TOPICS: Parkinson disease, levodopa, L-dopa analog, cross blood brain barrier, DOPA decarboxylase, carbidopa, increase bioavailability, peripheral DOPA decarboxylase inhibitor, decrease peripheral adverse effects of L-DOPA, reduce postural hypotension, nausea/vomiting, hot flashes, risk of arrhythmias, entacapone, tolcapone, inhibit COMT, hallucinations, confusion, anxiety, insomnia, agitation, delusion, on-off phenomenon, reducing dose, atypical antipsychotics
